A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation
Interventions: DRUG: SC10914
Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.